Akari appoints Samir Patel as interim CEO; merger with Peak Bio on track for Q4 2024

Akari Therapeutics Plc

Samir R. Patel appointed interim CEO with employment contract consisting solely of equity compensation.
Merger with Peak Bio remains on track for Q4 2024 closing; combined entity to focus on ADC platform and PAS-nomacopan for GA.
Raised $7.6M in private placement and issued $1M in convertible notes to CEO and Chairman for operating capital.
Reported net loss of $7.6M for Q2 2024 vs $4.0M in Q2 2023; cash at $4.2M at June 30, 2024.
Received positive pre-IND feedback from FDA for PAS-nomacopan in geographic atrophy; IND filing planned for H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.